Abstract
In press
Background. Surgical intervention remains the main method of treatment for patients with solid tumors, but such intervention can accelerate the development of tumor recurrence and/or metastasis in cancer patients. The search for effective drugs for perioperative treatment aimed at limiting the risks of cancer spread remains a relevant task. Repurposed drugs are a promising focus of attention due to their safety, availability, and potential ability to inhibit tumor progression.
Aim. To present data on the effects of antihypertensive, anti-inflammatory, antidiabetic, hypolipidemic, and antithrombotic drugs that have been identified during their perioperative use in cancer patients and to summarize the results of studies aimed at analyzing the long-term effects of perioperative treatment with these drugs.
Materials and Methods. Data for the review were searched using the PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases. Data from studies published between 2010 and 2026 were analyzed and systematized. The study was carried out within the research project "Development of a technology of anti-inflammatory perioperative therapy for radiofrequency ablation of colorectal cancer liver metastases" (2025–2027), state registration No.0124U003825.
Research Ethics. Sources describing studies conducted in compliance with ethical rules were analyzed.
Results. The review presents data on the effects of β-blockers, nonsteroidal anti-inflammatory drugs, metformin, statins, and antithrombotic drugs identified during their perioperative use in cancer patients. These agents are capable of exerting a direct effect on tumor cells, as well as modulating the systemic inflammatory response, angiogenesis, immune reactivity, metabolic processes, and thrombus formation, thereby potentially influencing disease progression. Data on postoperative survival of patients who underwent perioperative treatment with these drugs are provided; despite promising results, these data remain controversial and warrant further verification.
Conclusions. To date, no standard regimens for perioperative treatment of cancer patients have been developed. Given the numerous and complex processes that occur during surgical stress, the use of approaches involving drugs from different pharmacological groups may contribute to achieving better results.
Keywords: oncology, surgical treatment, perioperative period, survival.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI: 10.3322/caac.21834. PMID: 38572751.
O'Rourke K, Huddart S. Surgical stress response and cancer outcomes: a narrative review. Dig Med Res. 2020;3:65. DOI: 10.21037/dmr-20-94.
Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: A phase II randomized trial. Clin Cancer Res. 2020;26(8):1803-11. DOI: 10.1158/1078-0432.CCR-19-2641. PMID: 31754048.
Zhou L, Li Y, Li X, Chen G, Liang H, Wu Y, et al. Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J Immunol. 2016;196(8):3460-9. DOI: 10.4049/jimmunol.1501677. PMID: 26969754.
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth. 2014;26(2):106-17. DOI: 10.1016/j.jclinane.2013.10.004. PMID: 24480297.
Musselman RP, Bennett S, Li W, Mamdani M, Gomes T, van Walraven C, et al. Association between perioperative beta blocker use and cancer survival following surgical resection. Eur J Surg Oncol. 2018;44(8):1164-9. DOI: 10.1016/j.ejso.2018.05.012. PMID: 29858097.
Sakamoto A, Yagi K, Okamura T, Harada T, Usuda J. Perioperative administration of an intravenous beta-blocker landiolol hydrochloride in patients with lung cancer: A Japanese retrospective exploratory clinical study. Sci Rep. 2019;9(1):5217. DOI: 10.1038/s41598-019-41520-7. PMID: 30914694.
Choy C, Raytis JL, Smith DD, Duenas M, Neman J, Jandial R, Lew MW. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade. Oncol Rep. 2016;35(6):3135-42. DOI: 10.3892/or.2016.4710. PMID: 27035124.
Al-Niaimi A, Dickson EL, Albertin C, Karnowski J, Niemi C, Spencer R, et al. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecol Oncol. 2016;143(3):521-5. DOI: 10.1016/j.ygyno.2016.09.019. PMID: 27693123.
Wang LD, Gao X, Li JY, Yu HY, Su HW, Liu LZ, Qi J. Effects of preemptive analgesia with parecoxib sodium on haemodynamics and plasma stress hormones in surgical patients with thyroid carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3977-80. DOI: 10.7314/apjcp.2015.16.9.3977. PMID: 25987072.
Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, Abdulahad WH, Struys MMRF. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anesthesiology. 2022;136(5):843-60. DOI: 10.1097/ALN.0000000000004141. PMID: 35180291.
Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, et al. Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the patient's body mass index. J Natl Cancer Inst. 2018;110(10):1115-22. DOI: 10.1093/jnci/djy042. PMID: 29718396.
Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113 Suppl 1:i82-7. DOI: 10.1093/bja/aet464. PMID: 24464611.
Luyckx M, Verougstraete C, Jouret M, Sawadogo K, Waterkeyn M, Grandjean F, et al. Intraoperative ketorolac and outcomes after ovarian cancer surgery. J Clin Med. 2024;13(6):1546. DOI: 10.3390/jcm13061546. PMID: 38541772.
Forget P, Bouche G, Duhoux FP, Coulie PG, Decloedt J, Dekleermaker A, et al. Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS One. 2019;14(12):e0225748. DOI: 10.1371/journal.pone.0225748. PMID: 31800611.
de Castro Araujo BL, de Oliveira JL, Rezende JFN, Noguera WS, de Melo AC, Thuler LCS. Impact of non-steroidal anti-inflammatory drugs on recurrence and survival after melanoma surgery: A cohort study. Cancer Invest. 2020;38(7):415-23. DOI: 10.1080/07357907.2020.1793351. PMID: 32643437.
Mao S, Wu Y, Wang R, Guo Y, Yuan J, Ma W, et al. Intraoperative use of single dose of nonsteroidal anti-inflammatory drugs was not associated with cancer recurrence and mortality after bladder cancer surgery: a retrospective study. Ann Palliat Med. 2020;9(1):8-18. DOI: 10.21037/apm.2019.11.27. PMID: 32005058.
Schack A, Fransgaard T, Klein MF, Gögenur I. Perioperative use of nonsteroidal anti-inflammatory drugs decreases the risk of recurrence of cancer after colorectal resection: A cohort study based on prospective data. Ann Surg Oncol. 2019;26(12):3826-37. DOI: 10.1245/s10434-019-07600-8. PMID: 31313040.
Huang Z, Wang X, Zou Q, Zhuang Z, Xie Y, Cai D, et al. High platelet-to-lymphocyte ratio predicts improved survival outcome for perioperative NSAID use in patients with rectal cancer. Int J Colorectal Dis. 2020;35(4):695-704. DOI: 10.1007/s00384-020-03528-8. PMID: 32040733.
Grahn O, Lundin M, Lydrup ML, Angenete E, Rutegård M. Postoperative non-steroidal anti-inflammatory drug use and oncological outcomes of rectal cancer. BJS Open. 2021;5(1):zraa050. DOI: 10.1093/bjsopen/zraa050. PMID: 33609397.
Jiang W, Wang L, Zhang J, Shen H, Dong W, Zhang T, et al. Effects of postoperative non-steroidal anti-inflammatory drugs on long-term survival and recurrence of patients with non-small cell lung cancer. Medicine (Baltimore). 2018;97(39):e12442. DOI: 10.1097/MD.0000000000012442. PMID: 30278522.
Huang WW, Zhu WZ, Mu DL, Ji XQ, Nie XL, Li XY, et al. Perioperative management may improve long-term survival in patients after lung cancer surgery: A retrospective cohort study. Anesth Analg. 2018;126(5):1666-74. DOI: 10.1213/ANE.0000000000002886. PMID: 29517574.
Cai R, Liao X, Li G, Xiang J, Ye Q, Chen M, Feng S. The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer. World J Surg Oncol. 2023;21(1):358. DOI: 10.1186/s12957-023-03247-8. PMID: 37986068.
Lee BM, Rodriguez A, Mena G, Gottumukkala V, Mehran RJ, Rice DC, et al. Platelet-to-lymphocyte ratio and use of NSAIDs during the perioperative period as prognostic indicators in patients with NSCLC undergoing surgery. Cancer Control. 2016;23(3):284-94. DOI: 10.1177/107327481602300312. PMID: 27556669.
Choi JE, Villarreal J, Lasala J, Gottumukkala V, Mehran RJ, Rice D, et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 2015;4(6):825-33. DOI: 10.1002/cam4.428. PMID: 25756351.
Shaji S, Smith C, Forget P. Perioperative NSAIDs and long-term outcomes after cancer surgery: A systematic review and meta-analysis. Curr Oncol Rep. 2021;23(12):146. DOI: 10.1007/s11912-021-01133-8. PMID: 34748112.
Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: Perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res. 2012;18(18):4895-902. DOI: 10.1158/1078-0432.CCR-12-1087. PMID: 22753587.
Sorski L, Melamed R, Matzner P, Lavon H, Shaashua L, Rosenne E, Ben-Eliyahu S. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition. Brain Behav Immun. 2016;58:91-8. DOI: 10.1016/j.bbi.2016.05.017. PMID: 27235931.
Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin Cancer Res. 2017;23(16):4651-61. DOI: 10.1158/1078-0432.CCR-17-0152. PMID: 28490464.
Haldar R, Ricon-Becker I, Radin A, Gutman M, Cole SW, Zmora O, Ben-Eliyahu S. Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial. Cancer. 2020;126(17):3991-4001. DOI: 10.1002/cncr.32950. PMID: 32533792.
Ricon-Becker I, Haldar R, Shabat Simon M, Gutman M, Cole SW, Ben-Eliyahu S, Zmora O. Effect of perioperative COX-2 and beta-adrenergic inhibition on 5-year disease-free-survival in colorectal cancer: A pilot randomized controlled Colorectal Metastasis PreventIon Trial (COMPIT). Eur J Surg Oncol. 2023;49(3):655-61. DOI: 10.1016/j.ejso.2022.10.013.
Sakis N, Sorski L, Asraf E, Ricon-Becker I, Shaashua L, Haldar R, et al. Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. Front Pharmacol. 2026;17:1823113. DOI: 10.3389/fphar.2026.1823113. PMID: 42088573.
DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014;148(1):81-90. DOI: 10.1007/s10549-014-3141-1. PMID: 25253174.
Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821-30. DOI: 10.1007/s10549-012-2223-1. PMID: 22933030.
Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat. 2015;150(1):149-55. DOI: 10.1007/s10549-015-3307-5. PMID: 25682077.
Zamanian MY, Golmohammadi M, Yumashev A, Hjazi A, Toama MA, AbdRabou MA, et al. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways. Cell Biochem Funct. 2024;42(4):e4071. DOI: 10.1002/cbf.4071. PMID: 38863255.
Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest. 2014;32(4):150-7. DOI: 10.3109/07357907.2014.889706. PMID: 24605899.
Lord SR, Collins JM, Cheng WC, Haider S, Wigfield S, Gaude E, et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. Br J Cancer. 2020;122(2):258-65. DOI: 10.1038/s41416-019-0665-5. PMID: 31819193.
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22(4):427-32. DOI: 10.1038/nm.4055. PMID: 26950360.
Tsukioki T, Shien T, Tanaka T, Suzuki Y, Kajihara Y, Hatono M, et al. Influences of preoperative metformin on immunological factors in early breast cancer. Cancer Chemother Pharmacol. 2020;86(1):55-63. DOI: 10.1007/s00280-020-04092-2. PMID: 32533334.
Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial. Cancer. 2014;120(19):2986-95. DOI: 10.1002/cncr.28853. PMID: 24917306.
Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015;4(2):161-73. DOI: 10.1002/cam4.353. PMID: 25417601.
Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, et al. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016;143(3):466-71. DOI: 10.1016/j.ygyno.2016.10.011. PMID: 27745917.
Colov Tauby EP, Bojesen RD, Grube C, Miedzianogora REG, Buzquurz F, Fransgaard T, et al. Perioperative metformin treatment to reduce postoperative hyperglycemia after colon cancer surgery: A randomized clinical trial. Dis Colon Rectum. 2024;67(11):1403-12. DOI: 10.1097/DCR.0000000000003426. PMID: 39437217.
Nguyen MM, Martinez JA, Hsu CH, Sokoloff M, Krouse RS, Gibson BA, et al. Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. Eur J Cancer Prev. 2018;27(6):557-62. DOI: 10.1097/CEJ.0000000000000394. PMID: 28692586.
Curry J, Johnson J, Tassone P, Vidal MD, Menezes DW, Sprandio J, et al. Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope. 2017;127(8):1808-15. DOI: 10.1002/lary.26489. PMID: 28185288.
Seo YS, Kim YJ, Kim MS, Suh KS, Kim SB, Han CJ, et al. Association of metformin use with cancer-specific mortality in hepatocellular carcinoma after curative resection: A nationwide population-based study. Medicine (Baltimore). 2016;95(17):e3527. DOI: 10.1097/MD.0000000000003527. PMID: 27124061.
Khajeh E, Aminizadeh E, Moghadam AD, Ramouz A, Klotz R, Golriz M, et al. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. Cancer Med. 2023;12(19):19548-59. DOI: 10.1002/cam4.6569. PMID: 37737550.
Anselmino LE, Baglioni MV, Malizia F, Laluce NC, Etichetti CB, Marignac VLM, et al. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment. Sci Rep. 2021;11(1):8091. DOI: 10.1038/s41598-021-87525-z. PMID: 33854147.
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137-44. DOI: 10.1007/s10549-009-0507-x. PMID: 19728082.
Bjarnadottir O, Romero Q, Bendahl PO, Jirström K, Rydén L, Loman N, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138(2):499-508. DOI: 10.1007/s10549-013-2473-6. PMID: 23471651.
Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, et al. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. J Transl Med. 2015;13:133. DOI: 10.1186/s12967-015-0486-0. PMID: 25925673.
Bjarnadottir O, Kimbung S, Johansson I, Veerla S, Jönsson M, Bendahl PO, et al. Global transcriptional changes following statin treatment in breast cancer. Clin Cancer Res. 2015;21(15):3402-11. DOI: 10.1158/1078-0432.CCR-14-1403. PMID: 25840970.
Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC, Lee SC. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7(3):2532-44. DOI: 10.18632/oncotarget.6304. PMID: 26565813.
Kamal A, Boerner J, Assad H, Chen W, Simon MS. The effect of statins on markers of breast cancer proliferation and apoptosis in women with in situ or early-stage invasive breast cancer. Int J Mol Sci. 2024;25(17):9587. DOI: 10.3390/ijms25179587. PMID: 39273534.
Longo J, Hamilton RJ, Masoomian M, Khurram N, Branchard E, Mullen PJ, et al. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):630-7. DOI: 10.1038/s41391-020-0221-7. PMID: 32203069.
Joliat GR, Gaspar-Figueiredo S, Labgaa I, Vrochides D, Perinel J, Adham M, et al. Impact of preoperative statin medication on long-term outcomes after pancreatoduodenectomy for ductal adenocarcinoma: an international multicentric cross-sectional study. J Cancer Res Clin Oncol. 2023;149(19):17007-14. DOI: 10.1007/s00432-023-05426-2. PMID: 37740766.
Löffler L, Gögenur I, Gögenur M. Correlations between preoperative statin treatment with short- and long-term survival following colorectal cancer surgery: a propensity score-matched national cohort study. Int J Colorectal Dis. 2024;39(1):60. DOI: 10.1007/s00384-024-04631-w. PMID: 38676763.
Seth R, Tai LH, Falls T, de Souza CT, Bell JC, Carrier M, et al. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann Surg. 2013;258(1):158-68. DOI: 10.1097/SLA.0b013e31826fcbdb. PMID: 23108132.
Mitsis M, Koliou P, Bali C, Ntounousi E, Tatsis V, Nousias V, et al. In surgical colon cancer patients extended-duration thromboprophylaxis (30 days) with the highest dose of tinzaparin (4,500 IU s.c./q.d.) normalizes the postoperative VEGF levels. J Cancer. 2017;8(15):2899-906. DOI: 10.7150/jca.20107. PMID: 28928880.
Yamaoka Y, Ikeda M, Ikenaga M, Murakami H, Haraguchi N, Miyake M, et al. Anti-metastatic effect of short-term postoperative anticoagulation for patients undergoing curative resection of colorectal cancer. Anticancer Res. 2016;36(10):5425-9. DOI: 10.21873/anticanres.11120. PMID: 27798910.
Auer RC, Ott M, Karanicolas P, Brackstone MR, Ashamalla S, Weaver J, et al. Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. BMJ. 2022;378:e071375. DOI: 10.1136/bmj-2022-071375. PMID: 36100263.
Wei Y, Li W, Lin J, Wang D, Dang C, Diao D, Zhang X. Prognostic value of anticoagulants in resectable gastric cancer. Research Square [Preprint]. 2024. DOI: 10.21203/rs.3.rs-3982052/v1.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
